Upadacitinib for treating severe rheumatoid arthritis – guidance (TA665)

Upadacitinib is recommended for rheumatoid arthritis in adults after an inadequate response to a combination of conventional DMARDs, or 1 biological DMARD where rituximab is inappropriate, or where rituximab has also provided inadequate response.

Source:

National Institute for Health and Care Excellence